Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENOVID vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropins (LH, FSH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining to impair implantation.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Oral contraception,Treatment of endometriosis,Dysfunctional uterine bleeding,Postponement of menstruation
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
Oral, 5 mg daily for 20 days starting on day 5 of menstrual cycle for ovulation inhibition; for endometriosis, 5 mg daily for 15 days increasing to 10 mg daily if breakthrough bleeding occurs.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Norethynodrel: 5-12 hours; mestranol: 7-20 hours. Terminal half-life of ethinyl estradiol from mestranol conversion: 10-30 hours. Clinical context: steady-state achieved after 3-5 half-lives (3-5 days).
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Hepatic via CYP3A4; norethynodrel is metabolized to norethindrone; mestranol is demethylated to ethinyl estradiol; metabolites undergo glucuronidation and sulfation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal (30-50% as metabolites, <5% unchanged) and fecal (40-60% via bile, mostly as glucuronide conjugates).
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norethynodrel: 95-97% bound to albumin; mestranol: >95% bound to albumin and sex hormone-binding globulin (SHBG).
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norethynodrel: ~2.0 L/kg; mestranol: ~3.5 L/kg. High Vd indicates extensive tissue distribution.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: 80-100% for norethynodrel; mestranol: 40-60% (first-pass metabolism to ethinyl estradiol).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No specific dose adjustment guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential fluid retention.
No data available for fictional drug ALYACEN 777.
Contraindicated in severe hepatic impairment (Child-Pugh C); in mild to moderate impairment (Child-Pugh A or B), reduce dose by 50% or use alternative therapy.
No data available for fictional drug ALYACEN 777.
Not recommended for use in pediatric patients for contraception; for endometriosis in adolescents, dose same as adult adjusted for weight (0.1-0.2 mg/kg/day norethynodrel equivalent, max 5 mg/day).
No data available for fictional drug ALYACEN 777.
Not indicated for contraception in postmenopausal women; if used for other indications, monitor for thromboembolic events and electrolyte disturbances; initiate at lowest effective dose (2.5 mg/day).
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events; contraindicated in women over 35 who smoke.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders (stroke, MI, DVT, PE), hepatic neoplasia, gallbladder disease, hypertension, glucose intolerance, and depression. Discontinue if jaundice or visual disturbances occur.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast carcinoma, undiagnosed abnormal genital bleeding, pregnancy, known or suspected estrogen-dependent neoplasia, impaired liver function, history of cholestatic jaundice of pregnancy, heavy smoking (>15 cigarettes/day) in women over 35.
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No significant food interactions. Grapefruit juice may increase estrogen levels; avoid large amounts. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
First trimester: Risk of fetal cardiovascular defects, neural tube defects, and cleft lip/palate. Second and third trimesters: Possible feminization of male fetuses (hypospadias) and clitoral enlargement in females. Postnatal: Vaginal adenosis and clear cell adenocarcinoma of the vagina/cervix in females exposed in utero.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excretion into breast milk occurs; M/P ratio not established. Avoid use during breastfeeding due to potential hormonal effects on infant. Alternative contraception recommended.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Contraindicated in pregnancy. No dosing adjustments applicable; if inadvertent exposure occurs, immediately discontinue the drug and provide counseling regarding risks.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Monitor for thromboembolic events, especially in women over 35 who smoke. Use lowest effective dose for shortest duration. Discontinue 4 weeks before elective surgery to reduce clotting risk. Not recommended for contraception due to high estrogen dose.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take at same time daily with food to reduce nausea.,Report symptoms of blood clots: chest pain, sudden shortness of breath, leg pain/swelling, severe headache, vision changes.,Do not use if pregnant or breastfeeding; seek alternative contraception.,Smoking increases risk of serious cardiovascular side effects.,Use backup contraception if vomiting occurs within 4 hours of dose.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENOVID vs ALYACEN 777, answered by our medical review team.
ENOVID is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropins (LH, FSH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining to impair implantation.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENOVID and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENOVID is: Oral, 5 mg daily for 20 days starting on day 5 of menstrual cycle for ovulation inhibition; for endometriosis, 5 mg daily for 15 days increasing to 10 mg daily if breakthrough bleeding occurs.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENOVID and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENOVID is classified as Category C. First trimester: Risk of fetal cardiovascular defects, neural tube defects, and cleft lip/palate. Second and third trimesters: Possible feminization of male fetuses (hypospadias) a. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.